Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,378,423

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,378,423 protect, and when does it expire?

Patent 7,378,423 protects MEKINIST and is included in one NDA.

This patent has fifty patent family members in twenty-nine countries.

Summary for Patent: 7,378,423
Title:Pyrimidine compound and medical use thereof
Abstract: The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] ##STR00001## wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.
Inventor(s): Kawasaki; Hisashi (Osaka, JP), Abe; Hiroyuki (Osaka, JP), Hayakawa; Kazuhide (Osaka, JP), Iida; Tetsuya (Osaka, JP), Kikuchi; Shinichi (Osaka, JP), Yamaguchi; Takayuki (Osaka, JP), Nanayama; Toyomichi (Osaka, JP), Kurachi; Hironori (Osaka, JP), Tamaru; Masahiro (Osaka, JP), Hori; Yoshikazu (Osaka, JP), Takahashi; Mitsuru (Osaka, JP), Yoshida; Takayuki (Yokohama, JP), Sakai; Toshiyuki (Kyoto, JP)
Assignee: Japan Tobacco Inc. (Tokyo, JP)
Application Number:11/150,792
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,378,423

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-001 May 29, 2013 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-002 May 29, 2013 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-003 May 29, 2013 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,378,423

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-174770Jun 11, 2004
Japan2004-327111Nov 10, 2004

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.